藥品參考
Enasidenib
Enasidenib is a medicine in the class oncology.
- 藥物類別: Oncology
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- 常見劑型
- 錠劑
- 已知交互作用
- 5 (嚴重: 1 · 中度: 4)
- 商品名
- 1
- 國家與市場
- 1
作用方式
Small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2); targets mutant IDH2 variants R140Q, R172S and R172K, decreasing 2-hydroxyglutarate levels and inducing myeloid differentiation.
成人常用劑量（仿單摘要）
Relapsed or refractory AML with IDH2 mutation: 100 mg orally once daily with or without food until disease progression or unacceptable toxicity; treat for a minimum of 6 months in patients without progression or unacceptable toxicity to allow clinical response
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: in rats and rabbits it caused embryo-fetal death and growth changes from 0.1 times human exposure; no human data. Verify pregnancy status. Use effective contraception during and for 2 months after; it can make hormonal pills less effective.
- 哺乳
- Unsafe No milk data. Because of possible adverse reactions in the infant, do not breastfeed during treatment and for 2 months after the last dose.
已通報的副作用
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Elevated bilirubin
- Differentiation syndrome
黑框警語
- Differentiation syndrome can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
禁忌症
- None.
哪些人需要特別留意
- Differentiation syndrome occurred in 14% of patients, as early as 1 day and up to 5 months after initiation; treat with corticosteroids (e.g., dexamethasone 10 mg every 12 hours) and hemodynamic monitoring; taper only after symptom resolution.
- Embryo-fetal toxicity: can cause fetal harm; verify pregnancy status before starting and use effective non-hormonal contraception during treatment and for 2 months after the last dose.
- Elevated bilirubin due to UGT1A1 inhibition; 37% of patients had total bilirubin ≥2 x ULN at least once.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (5)
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Enasidenib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
相關快速閱讀
常見問題
What is Enasidenib used for?
Enasidenib is a medicine in the class oncology.
What side effects have been reported with Enasidenib?
Nausea, Diarrhea, Vomiting, Decreased appetite, Elevated bilirubin, Differentiation syndrome. Serious warning: Differentiation syndrome can be fatal if not treated.
Can Enasidenib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats and rabbits it caused embryo-fetal death and growth changes from 0.1 times human exposure; no human data. Verify pregnancy status. Use effective contraception during and for 2 months after; it can make hormonal pills less effective. Breastfeeding: Unsafe. No milk data. Because of possible adverse reactions in the infant, do not breastfeed during treatment and for 2 months after the last dose.
What does Enasidenib interact with?
MediHelp lists 5 known interactions for Enasidenib. Major: 1 · Moderate: 4. The most serious include Rosuvastatin, Desogestrel-ethinyl estradiol, Ethinyl estradiol-levonorgestrel.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
